These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20411994)

  • 1. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 2. Contaminant in the recalled unfractionated heparin preparations: where is the problem?
    Hoppensteadt DA; Wahi R; Adiguzel C; Iqbal O; Ramacciotti E; Bick RL; Messmore HL; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):261-6. PubMed ID: 18565985
    [No Abstract]   [Full Text] [Related]  

  • 3. Tainted heparin crisis tested FDA's investigative skills.
    Lavine G
    Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
    Williams RL; ;
    J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 7. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 8. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 10. The US regulatory and pharmacopeia response to the global heparin contamination crisis.
    Szajek AY; Chess E; Johansen K; Gratzl G; Gray E; Keire D; Linhardt RJ; Liu J; Morris T; Mulloy B; Nasr M; Shriver Z; Torralba P; Viskov C; Williams R; Woodcock J; Workman W; Al-Hakim A
    Nat Biotechnol; 2016 Jun; 34(6):625-30. PubMed ID: 27281424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of currently marketed heparin products: key tests for quality assurance.
    Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
    Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparins: process-related physico-chemical and compositional characteristics, fingerprints and impurities.
    Liverani L; Mascellani G; Spelta F
    Thromb Haemost; 2009 Nov; 102(5):846-53. PubMed ID: 19888518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
    Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
    Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Readers are asked to respond on heparin prescription and administration.
    Dinwiddie LC
    Nephrol Nurs J; 2003 Feb; 30(1):81. PubMed ID: 12674957
    [No Abstract]   [Full Text] [Related]  

  • 16. Extemporaneously compounded sterile medications: relevance of new United States pharmacopeial standards to pain clinicians.
    Rusho WJ
    J Pain Palliat Care Pharmacother; 2004; 18(4):69-76. PubMed ID: 15760810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regulatory process.
    Hung JC; Callahan RJ
    J Nucl Med; 2004 Jan; 45(1):13N-14N, 16N. PubMed ID: 14734661
    [No Abstract]   [Full Text] [Related]  

  • 18. Do different heparin brands influence activated clotting times?
    Dyck L; Friesen RM
    J Extra Corpor Technol; 1998 Jun; 30(2):73-6. PubMed ID: 10182116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from contaminated heparin.
    Dodd S; Besag FM
    Curr Drug Saf; 2009 Jan; 4(1):1. PubMed ID: 19149518
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening of heparin API by near infrared reflectance and Raman spectroscopy.
    Spencer JA; Kauffman JF; Reepmeyer JC; Gryniewicz CM; Ye W; Toler DY; Buhse LF; Westenberger BJ
    J Pharm Sci; 2009 Oct; 98(10):3540-7. PubMed ID: 19117047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.